Why Some Keep It Off What accounts for the difference
The target dose is 2.4 mg injected subcutaneously once per week
Phase 2: Introduce AOD 9604 (weeks 5-8) Once tirzepatide is tolerated at the initial dose, add AOD 9604 at 250mcg daily
In the future, the focus should be on its reproductive safety, long-term efficacy, and integration with other therapies, ultimately achieving effective transformation from basic research to clinical practice
While the company did not publicly disclose specific reasons for discontinuation, the lack of statistically significant dose-response at Week 8 in the Phase 2b trial, likely contributed to the decision not to pursue further development in UC
How Sermorelin Therapy Works at Our West Palm Beach Clinic Before starting treatment, providers at our West Palm Beach clinic follow a structured process focused on medical evaluation, patient education, and ongoing provider oversight